查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602742

心絞痛治療藥物市場：按類型、藥物、給藥途徑、分銷管道和最終用戶分類 - 全球預測 2025-2030

Angina Pectoris Drugs Market by Type (Prinzmetal Angina, Stable Angina, Unstable Angina), Drugs (Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents), Route of Administration, Distribution Channel, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年心絞痛治療市場價值為11.4億美元，預計到2024年將達到12億美元，複合年成長率為5.39%，到2030年預計將達到16.5億美元。

心絞痛藥物的範圍包括治療和管理與心臟供血不足引起的胸痛相關的症狀。此類別包括硝酸鹽、 BETA阻斷劑、鈣通道阻斷劑和抗血小板藥物等藥物，這些藥物對於緩解心絞痛症狀和預防心臟病發作至關重要。全球心血管疾病的流行和老年人口的不斷成長強調了對這些藥物的需求，這使得它們在慢性病護理管理中至關重要。它的用途不僅僅是緩解症狀，對於改善患者的生活品質和降低主要心血管事件的發生率至關重要。主要的最終用途市場包括醫院、診所和零售藥房，由於醫療保健基礎設施和意識的不斷增強，新興市場的使用量不斷增加。

主要市場統計
基準年[2023] 11.4億美元
預測年份 [2024] 12億美元
預測年份 [2030] 16.5億美元
複合年成長率（%） 5.39%

市場開拓和個人化醫療的進步以及醫療保健支出的增加是市場成長的關鍵驅動力。新的商機在於在持續研究和藥物創新的推動下，開發針對冠狀動脈疾病特定途徑的新型療法。對預防性醫療保健和生活方式改善的日益關注為市場滲透提供了進一步的機會。然而，成長受到嚴格的法規環境、開發新藥的高成本以及導致患者違規的潛在副作用的限制。

主要挑戰包括因專利到期而面臨的學名藥競爭，以及在低收入市場中平衡有效性和價格的需要。基因治療、組合藥物開發以及利用人工智慧預測患者反應和最佳化配方等領域的創新可能會取得進展。透過了解複雜的患者需求並投資於研發，我們可以取得突破。透過策略夥伴關係關係和本地市場滲透積極主動地拓展市場可以提高可及性。心絞痛治療市場充滿活力，在臨床創新的推動下具有巨大的成長潛力，但必須克服監管和經濟挑戰才能充分實現這一前景。

市場動態：快速發展的心絞痛治療市場的關鍵市場洞察

供需的動態交互作用正在改變心絞痛藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 由於心臟相關疾病的增加，文明病的負擔增加
    • 新藥物輸送系統的增加
    • 政府支持加強心血管疾病防治
  • 市場限制因素
    • 對特定藥物類別相關副作用的擔憂
  • 市場機會
    • 個人化心血管照護的技術進步
    • 藥品核准和臨床研究快速成長
  • 市場挑戰
    • 缺乏技術精湛、經驗豐富的專業人員

波特五力：駕馭心絞痛藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對心絞痛治療市場的影響

外部宏觀環境因素在塑造心絞痛治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解心絞痛治療藥物市場的競爭狀況

對心絞痛治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣心絞痛治療市場供應商的績效評估

FPNV 定位矩陣是評估心絞痛治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪心絞痛治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對心絞痛治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 與文明病負擔增加以及與心臟相關的疾病增加
      • 增強新的藥物傳輸系統
      • 政府支持加強心血管疾病防治
    • 抑制因素
      • 對特定藥物類別相關副作用的擔憂
    • 機會
      • 個性化心血管醫學的技術進步
      • 增加藥物核准和臨床研究
    • 任務
      • 缺乏技術精湛、經驗豐富的專業人員
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章心絞痛治療藥物市場：依類型

  • 變異型心絞痛
  • 穩定型心絞痛
  • 不穩定型心絞痛

第7章：以市場藥品分類的心絞痛治療藥物

  • 抗缺血劑
  • 抗高血壓藥
  • 抗血小板藥
  • BETA受體阻斷劑
  • 鈣離子通道阻斷劑
  • 硝酸鹽
  • 他汀類藥物

第8章 心絞痛治療藥物市場：依給藥途徑

  • 口服
  • 胃腸外的
  • 經皮

第9章心絞痛治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第 10 章 心絞痛治療藥物市場：依最終使用者分類

  • 居家護理
  • 醫院
  • 專科診所

第11章美洲心絞痛藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章：亞太心絞痛藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章：歐洲、中東和非洲心絞痛治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Centurion Remedies Private Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Intas Pharmaceuticals Ltd.
  • Ipca Laboratories Ltd.
  • Lupin Ltd.
  • Macleods Pharmaceuticals Pvt Ltd.
  • Mankind Pharma
  • Merck & Co. Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi-Aventis Groupe SA
  • Sumitomo Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
Product Code: MRR-742BD517AD07

The Angina Pectoris Drugs Market was valued at USD 1.14 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 5.39%, to USD 1.65 billion by 2030.

The scope of angina pectoris drugs encompasses the treatment and management of symptoms associated with chest pain resulting from insufficient blood flow to the heart. This category includes medications like nitrates, beta-blockers, calcium channel blockers, and antiplatelet agents, which are crucial for alleviating angina symptoms and preventing heart attacks. The necessity of these drugs is underscored by the global prevalence of cardiovascular diseases and the rising geriatric population, making them indispensable in chronic care management. Their applications extend beyond symptom relief; they're integral in improving patient quality of life and reducing the incidence of major cardiovascular events. Primary end-use markets include hospitals, clinics, and retail pharmacies, with expanding reach in developing regions due to increasing health infrastructure and awareness.

KEY MARKET STATISTICS
Base Year [2023] USD 1.14 billion
Estimated Year [2024] USD 1.20 billion
Forecast Year [2030] USD 1.65 billion
CAGR (%) 5.39%

Market growth is predominantly influenced by advancements in drug development and personalized medicine, alongside increasing healthcare expenditures. Emerging opportunities lie in the development of novel therapeutics targeting specific pathways involved in coronary artery disease, driven by ongoing research and technological innovations in pharmaceuticals. An increasing focus on preventive care and lifestyle modifications presents further opportunities for market penetration. However, growth is tempered by stringent regulatory environments, high costs of novel drug development, and potential side effects leading to patient non-compliance.

Key challenges include the competition from generics due to patent expirations and the need to balance efficacy with affordability in low-income markets. Innovation can flourish in areas such as gene therapy, development of combination drugs, and leveraging artificial intelligence to better predict patient responses and optimize drug formulations. Understanding complex patient needs and investing in R&D can lead to breakthroughs. A proactive approach to market expansion through strategic partnerships and rural market penetration can enhance accessibility. The angina pectoris drugs market is dynamic, with significant potential for growth driven by clinical innovation, yet it requires navigating through regulatory and economic challenges to fully realize these prospects.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Angina Pectoris Drugs Market

The Angina Pectoris Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
    • Augmentation of novel drug delivery systems
    • Government suppport in strengthening the prevention and control of cardiovascular disease
  • Market Restraints
    • Concerns regarding side effects associated with certain drug classes
  • Market Opportunities
    • Technological advancements towards personalized cardiovascular medicine
    • Proliferation in the number of drug approvals and clinical research
  • Market Challenges
    • Dearth of skilled and experienced professionals

Porter's Five Forces: A Strategic Tool for Navigating the Angina Pectoris Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Angina Pectoris Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Angina Pectoris Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Angina Pectoris Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Angina Pectoris Drugs Market

A detailed market share analysis in the Angina Pectoris Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Angina Pectoris Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Angina Pectoris Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Angina Pectoris Drugs Market

A strategic analysis of the Angina Pectoris Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Angina Pectoris Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Centurion Remedies Private Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Mankind Pharma, Merck & Co. Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sumitomo Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Angina Pectoris Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Prinzmetal Angina, Stable Angina, and Unstable Angina.
  • Based on Drugs, market is studied across Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Nitrates, and Statins.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Transdermal.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
      • 5.1.1.2. Augmentation of novel drug delivery systems
      • 5.1.1.3. Government suppport in strengthening the prevention and control of cardiovascular disease
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding side effects associated with certain drug classes
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements towards personalized cardiovascular medicine
      • 5.1.3.2. Proliferation in the number of drug approvals and clinical research
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of skilled and experienced professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Angina Pectoris Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Prinzmetal Angina
  • 6.3. Stable Angina
  • 6.4. Unstable Angina

7. Angina Pectoris Drugs Market, by Drugs

  • 7.1. Introduction
  • 7.2. Anti-Ischemic Agents
  • 7.3. Antihypertensive Agents
  • 7.4. Antiplatelet Agents
  • 7.5. Beta-Adrenergic Blocking Agents
  • 7.6. Calcium Channel Blockers
  • 7.7. Nitrates
  • 7.8. Statins

8. Angina Pectoris Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Transdermal

9. Angina Pectoris Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Angina Pectoris Drugs Market, by End-Users

  • 10.1. Introduction
  • 10.2. Homecare
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Angina Pectoris Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Angina Pectoris Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Angina Pectoris Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alembic Pharmaceuticals Limited
  • 2. Alkem Laboratories Ltd.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Bausch Health Companies Inc.
  • 6. Bayer AG
  • 7. Centurion Remedies Private Limited
  • 8. Dr. Reddy's Laboratories
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Intas Pharmaceuticals Ltd.
  • 13. Ipca Laboratories Ltd.
  • 14. Lupin Ltd.
  • 15. Macleods Pharmaceuticals Pvt Ltd.
  • 16. Mankind Pharma
  • 17. Merck & Co. Inc.
  • 18. Novartis AG
  • 19. Otsuka Pharmaceutical Co., Ltd.
  • 20. Pfizer Inc.
  • 21. Sanofi-Aventis Groupe S.A.
  • 22. Sumitomo Corporation
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Torrent Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. ANGINA PECTORIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANGINA PECTORIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANGINA PECTORIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANGINA PECTORIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANGINA PECTORIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANGINA PECTORIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY PRINZMETAL ANGINA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ANTI-ISCHEMIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY BETA-ADRENERGIC BLOCKING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY NITRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 240. ANGINA PECTORIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. ANGINA PECTORIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023